Ghisallo Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Ghisallo Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28,893	Closed	-$292K	–	165
2022 Q4	$292K	Sell	28,893 -95,907	-77%	-$959K	0.05%	122
2022 Q3	$1.24M	Sell	124,800 -200	-0.2%	-$1.97K	0.17%	198
2022 Q2	$1.22M	Hold	125,000	–	–	0.15%	213
2022 Q1	$1.22M	Hold	125,000	–	–	0.13%	237
2021 Q4	$1.21M	Hold	125,000	–	–	0.06%	359
2021 Q3	$1.21M	Hold	125,000	–	–	0.05%	361
2021 Q2	$1.21M	Buy	+125,000	New	+$1.23M	0.05%	352

Ghisallo Capital Management's EBAC Position: Q1 2023 in Review

Ghisallo Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 28,893 shares — an estimated $292K sold.

Ghisallo Capital Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $1.24M in Q3 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Ghisallo Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Ghisallo Capital Management sold 28,893 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $292K.
Ghisallo Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Ghisallo Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $1.24M in Q3 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Ghisallo Capital Management's 13F filing for Q1 2023, filed 15 May 2023.